ClinicalTrials.gg
RecruitingNCT07869511Updated Oct 9, 2026

OCTA Evaluated the Efficacy of Glucocorticoid Retrobulbar Injection in Retinal Photo-injury

An observational study in Retinal Light Damage, Photic Retinopathy and Photic Maculopathy, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 1 site in China. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Observational

Updated Oct 9, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
50
Ages
6 Years and older
Sex
All
01

Study summary

The goal of this retrospective observational study is to evaluate the effectiveness of retrobulbar glucocorticoid injection in patients with retinal photo-injury. The main questions it aims to answer are:

Does retrobulbar glucocorticoid injection improve visual outcomes in patients with retinal photo-injury? Does retrobulbar glucocorticoid injection promote recovery of retinal structural and microvascular changes assessed by optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA)? Patients with retinal photo-injury will be retrospectively identified and grouped according to the treatment they received. Clinical and ophthalmic data collected before treatment and during follow-up for up to 6 months will be reviewed, including best-corrected visual acuity (BCVA), fundus photography, spectral-domain OCT (SD-OCT), and OCTA. Visual and retinal imaging outcomes will be compared between the two groups to evaluate the potential effectiveness of retrobulbar glucocorticoid treatment.

02

Conditions studied

  • Retinal Light Damage
  • Photic Retinopathy
  • Photic Maculopathy
03

In context

Lead sponsor

Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 100 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients diagnosed with retinal photic injury

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The diagnosis was established based on a history of exposure to a high-intensity light source and clinical manifestations such as metamorphopsia and reduced visual acuity, combined with findings from fundus examination and OCT-specifically, disruption or defects in the photoreceptor inner/outer segment (IS/OS) junction and the retinal pigment epithelium (RPE) layer within the macular region.

The included patient should meet the aforementioned diagnostic criteria, and was diagnosed with retinal photic injury.

Exclusion criteria

Exclusion Criteria:

  1. Unable or unwilling to sign the form, or unable to adhere to study procedures.
  2. Patients have conditions that significantly interfere with OCTA imaging, such as severe corneal opacity, cataracts, or vitreous hemorrhage.
  3. Patients who develop other concurrent eye diseases or severe comorbidities requiring immediate treatment during the follow-up period-such as glaucoma, uveitis, scleritis, retinal detachment, optic neuritis, diabetic retinopathy, macular hole, retinal neovascularization, sclerosis, Parkinson's disease, or other disorders affecting the retina and optic nerve.
  4. History of intraocular surgery or ocular trauma.
  5. Severe systemic diseases (e.g., serious cardiovascular, cerebrovascular, or hematopoietic disorders), or a history of intracranial surgery or intracranial space-occupying lesions.
  6. Inability to cooperate with ophthalmic examinations or failure to obtain satisfactory OCTA images for other reasons.
  7. Pregnant women, women planning pregnancy or breastfeeding, and patients with drug allergies.
  8. Suspected or confirmed history of alcohol or drug abuse.
  9. Patients currently participating in other clinical trials involving medications.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Local hormone treatment group

    Patients with retinal photic injury who only received intravitreal corticosteroid injections during their initial visit and follow-ups were placed in the local hormone treatment group.

    Drug: retrobulbar injection of glucocorticoid

  • Non-hormone treatment group

    Patients with retinal light damage who didn't use any systemic or local corticosteroid treatment at their first visit or during follow-ups were placed in the non-hormone treatment group.

Interventions

  • Drugretrobulbar injection of glucocorticoid

    Retrobulbar injection of Methylprednisolone (40mg/ml) once a week, or triamcinolone (40mg/ml) every 2-3 weeks, no more than 3 times in a row. For children, the dose should be halved or the interval extended, and closely watch for any side effects after injection.

06

What researchers measure

Primary outcomes

  1. Changes in Best-Corrected Visual Acuity (BCVA), measured in logMAR

    Best-corrected visual acuity (BCVA) will be assessed using a standardized visual acuity chart after appropriate refractive correction and recorded as a decimal visual acuity value, which will be converted to the logarithm of the minimum angle of resolution (logMAR) for statistical analysis. BCVA will be assessed at baseline (before treatment) and at 1 week, 2 weeks, 1 month, 3 months, and 6 months after treatment. The BCVA value and the change from baseline at each follow-up time point will be summarized and compared. Lower logMAR values indicate better visual acuity.

    Time frame: Before treatment and at 1 week, 2 weeks, 1 month, 3 months, and 6 months after treatment

Secondary outcomes

  1. Changes in Central Subfield Thickness, Ellipsoid Zone Defect Length, and Outer Nuclear Layer Thickness Measured by Optical Coherence Tomography

    Retinal structural changes will be assessed using optical coherence tomography (OCT). The following quantitative parameters will be measured: central subfield thickness (CST, μm), maximum horizontal length of the ellipsoid zone (EZ) defect (μm), and foveal outer nuclear layer (ONL) thickness (μm). Measurements will be obtained at baseline (before treatment) and at 1 week, 2 weeks, 1 month, 3 months, and 6 months after treatment. Each parameter and its change from baseline at each follow-up time point will be summarized and compared to evaluate retinal structural recovery following treatment.

    Time frame: Before treatment and at 1 week, 2 weeks, 1 month, 3 months, and 6 months after treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2026
First posted
Oct 9, 2026
StartEst.
Oct 9, 2026
Primary completionEst.
Oct 9, 2027
CompletionEst.
Oct 9, 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07869511
Responsible party
Sponsor
First posted
Oct 9, 2026
Start date
Oct 9, 2026 (estimated)
Primary completion
Oct 9, 2027 (estimated)
Completion
Oct 9, 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

zhiyong zhang
Contact
zhangzhiyong@zju.edu.cn
+86 13968059392

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion